The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
Open accessAbstract
Middle East respiratory syndrome (MERS) is an emerging infectious disease associated with a relatively high mortality rate of approximately 40%. MERS is caused by MERS coronavirus (MERS-CoV) infection, and no specific drugs or vaccines are currently available to prevent MERS-CoV infection. MERS-CoV is an enveloped virus, and its envelope protein (S protein) mediates membrane fusion at the plasma membrane or endosomal membrane. Multiple proteolysis by host proteases, such as furin, transmembrane protease serine 2 (TMPRSS2), and cathepsins, causes the S protein to become fusion competent. TMPRSS2, which is localized to the plasma membrane, is a serine protease responsible for the proteolysis of S in the post-receptor-binding stage. Here, we developed a cell-based fusion assay for S in a TMPRSS2-dependent manner using cell lines expressing Renilla luciferase (RL)-based split reporter proteins. S was stably expressed in the effector cells, and the corresponding receptor for S, CD26, was stably coexpressed with TMPRSS2 in the target cells. Membrane fusion between these effector and target cells was quantitatively measured by determining the RL activity. The assay was optimized for a 384-well format, and nafamostat, a serine protease inhibitor, was identified as a potent inhibitor of S-mediated membrane fusion in a screening of about 1,000 drugs approved for use by the U.S. Food and Drug Administration. Nafamostat also blocked MERS-CoV infection in vitro . Our assay has the potential to facilitate the discovery of new inhibitors of membrane fusion of MERS-CoV as well as other viruses that rely on the activity of TMPRSS2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T. M., Raj, V. S., Zaki, A. M., Osterhaus, A. D. M. E., Haagmans, B. L., Gorbalenya, A. E., Snijder, E. J., et al. (2012) · mBio · doi:10.1128/mbio.00473-12 · Cited by 914
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
Millet, J. K., & Whittaker, G. R. (2015) · Virus Research · doi:10.1016/j.virusres.2014.11.021 · Cited by 902
Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., & Taguchi, F. (2010) · Journal of Virology · doi:10.1128/jvi.01542-10 · Cited by 778
Self-citationMolecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., et al. (2013) · Nature · doi:10.1038/nature12328 · Cited by 739
Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics
Kitamura, T., Koshino, Y., Shibata, F., Oki, T., Nakajima, H., Nosaka, T., & Kumagai, H. (2003) · Experimental Hematology · doi:10.1016/j.exphem.2003.07.005 · Cited by 737
Millet, J. K., & Whittaker, G. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407087111 · Cited by 698
Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond
Lu, G., Wang, Q., & Gao, G. F. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.06.003 · Cited by 607
Böttcher, E., Matrosovich, T., Beyerle, M., Klenk, H.-D., Garten, W., & Matrosovich, M. (2006) · Journal of Virology · doi:10.1128/jvi.01118-06 · Cited by 489
Cited by
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Coronavirus biology and replication: implications for SARS-CoV-2
V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,197
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Bonaventura, A., Vecchié, A., Dagna, L., Martinod, K., Dixon, D. L., Van Tassell, B. W., Dentali, F., Montecucco, F., Massberg, S., Levi, M., et al. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00536-9 · Cited by 987
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications
McFadyen, J. D., Stevens, H., & Peter, K. (2020) · Circulation Research · doi:10.1161/circresaha.120.317447 · Cited by 592
Iba, T., Levy, J. H., Levi, M., & Thachil, J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14975 · Cited by 585
Candidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Hoffmann, M., Schroeder, S., Kleine-Weber, H., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00754-20 · Cited by 486
COVID-19-associated coagulopathy and disseminated intravascular coagulation
Asakura, H., & Ogawa, H. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03029-y · Cited by 442
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huettenhain, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.22.002386 · Cited by 395
TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections
Shen, L. W., Mao, H. J., Wu, Y. L., Tanaka, Y., & Zhang, W. (2017) · Biochimie · doi:10.1016/j.biochi.2017.07.016 · Cited by 285
Current epidemiological and clinical features of COVID-19; a global perspective from China
Tu, H., Tu, S., Gao, S., Shao, A., & Sheng, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.011 · Cited by 283
COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics
Yesudhas, D., Srivastava, A., & Gromiha, M. M. (2021) · Infection · doi:10.1007/s15010-020-01516-2 · Cited by 270
Yamamoto, M., Kiso, M., Sakai-Tagawa, Y., Iwatsuki-Horimoto, K., Imai, M., Takeda, M., Kinoshita, N., Ohmagari, N., Gohda, J., Semba, K., et al. (2020) · Viruses · doi:10.3390/v12060629 · Cited by 268
Self-citationMolecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
Verma, A. K., & Aggarwal, R. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13812 · Cited by 54
Yamamoto, M., Tomita, K., Hirayama, Y., Inoue, J.-I., Kawaguchi, Y., & Gohda, J. (2022) · doi:10.1101/2022.03.21.485084 · Cited by 36
Self-citationFighting COVID-19 with Artificial Intelligence
Monteleone, S., Kellici, T. F., Southey, M., Bodkin, M. J., & Heifetz, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_3 · Cited by 17
Metadata
- Authors
- Yamamoto, M., Matsuyama, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J.-I., & Matsuda, Z.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-11
- Volume
- 60
- Issue
- 11
- Pages
- 6532-6539
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2509449660
- Cited by
- 340
- References
- 34
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.